Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: NCI Will Use Genomics Collaborative Data for Hypertension Research

NEW YORK, April 8 - Genomics Collaborative said today that it has agreed to let the US National Cancer Institute use its repository of DNA samples so it can validate some earlier discoveries.

The NCI, which approached GCI in this deal, will use DNA samples from 6,000 people to see if a specific receptor gene increases an individual's risk of developing hypertension. An equal number of samples are from people with and without hypertension.

The project should take three to six months to complete, said Mike Pellini, CEO of GCI. 

Financial terms of the deal, which is the first time GCI has collaborated with the NCI, were not disclosed.


And why, pray tell, is the NCI, the nation's top cancer-research facility, studying hypertension? In one of those prized moments of clinical serendipity, NCI researchers, while studying a receptor for HIV, found that knocking out a particular gene appeared to affect blood pressure.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.